EIKN (NASDAQ:EIKN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of EIKN (NASDAQ:EIKN) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $25.20.

EIKN has been the topic of a number of recent research reports. Wedbush cut their target price on EIKN from $7.00 to $5.00 and set an “underperform” rating on the stock in a report on Tuesday, May 12th. Bank of America began coverage on EIKN in a research note on Monday, March 2nd. They set a “buy” rating and a $34.00 price objective on the stock. JPMorgan Chase & Co. began coverage on EIKN in a research note on Monday, March 2nd. They set an “overweight” rating and a $29.00 price objective on the stock. Mizuho began coverage on EIKN in a research note on Monday, March 2nd. They set an “outperform” rating and a $26.00 price objective on the stock. Finally, Morgan Stanley assumed coverage on EIKN in a research note on Monday, March 2nd. They set an “overweight” rating and a $32.00 price objective on the stock.

EIKN Price Performance

Shares of EIKN stock opened at $10.91 on Friday. EIKN has a 52 week low of $7.90 and a 52 week high of $17.40. The stock’s 50 day moving average is $10.66.

EIKN (NASDAQ:EIKN) last issued its earnings results on Monday, March 30th. The company reported ($26.23) earnings per share (EPS) for the quarter.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.